Cargando…

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease

BACKGROUND & AIMS: Ammonia levels predicted hospitalisation in a recent landmark study not accounting for portal hypertension and systemic inflammation severity. We investigated (i) the prognostic value of venous ammonia levels (outcome cohort) for liver-related outcomes while accounting for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Balcar, Lorenz, Krawanja, Julia, Scheiner, Bernhard, Paternostro, Rafael, Simbrunner, Benedikt, Semmler, Georg, Jachs, Mathias, Hartl, Lukas, Stättermayer, Albert Friedrich, Schwabl, Philipp, Pinter, Matthias, Szekeres, Thomas, Trauner, Michael, Reiberger, Thomas, Mandorfer, Mattias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976454/
https://www.ncbi.nlm.nih.gov/pubmed/36873421
http://dx.doi.org/10.1016/j.jhepr.2023.100682
_version_ 1784899079967342592
author Balcar, Lorenz
Krawanja, Julia
Scheiner, Bernhard
Paternostro, Rafael
Simbrunner, Benedikt
Semmler, Georg
Jachs, Mathias
Hartl, Lukas
Stättermayer, Albert Friedrich
Schwabl, Philipp
Pinter, Matthias
Szekeres, Thomas
Trauner, Michael
Reiberger, Thomas
Mandorfer, Mattias
author_facet Balcar, Lorenz
Krawanja, Julia
Scheiner, Bernhard
Paternostro, Rafael
Simbrunner, Benedikt
Semmler, Georg
Jachs, Mathias
Hartl, Lukas
Stättermayer, Albert Friedrich
Schwabl, Philipp
Pinter, Matthias
Szekeres, Thomas
Trauner, Michael
Reiberger, Thomas
Mandorfer, Mattias
author_sort Balcar, Lorenz
collection PubMed
description BACKGROUND & AIMS: Ammonia levels predicted hospitalisation in a recent landmark study not accounting for portal hypertension and systemic inflammation severity. We investigated (i) the prognostic value of venous ammonia levels (outcome cohort) for liver-related outcomes while accounting for these factors and (ii) its correlation with key disease-driving mechanisms (biomarker cohort). METHODS: (i) The outcome cohort included 549 clinically stable outpatients with evidence of advanced chronic liver disease. (ii) The partly overlapping biomarker cohort comprised 193 individuals, recruited from the prospective Vienna Cirrhosis Study (VICIS: NCT03267615). RESULTS: (i) In the outcome cohort, ammonia increased across clinical stages as well as hepatic venous pressure gradient and United Network for Organ Sharing model for end-stage liver disease (2016) strata and were independently linked with diabetes. Ammonia was associated with liver-related death, even after multivariable adjustment (adjusted hazard ratio [aHR]: 1.05 [95% CI: 1.00–1.10]; p = 0.044). The recently proposed cut-off (≥1.4 × upper limit of normal) was independently predictive of hepatic decompensation (aHR: 2.08 [95% CI: 1.35–3.22]; p <0.001), non-elective liver-related hospitalisation (aHR: 1.86 [95% CI: 1.17–2.95]; p = 0.008), and – in those with decompensated advanced chronic liver disease – acute-on-chronic liver failure (aHR: 1.71 [95% CI: 1.05–2.80]; p = 0.031). (ii) Besides hepatic venous pressure gradient, venous ammonia was correlated with markers of endothelial dysfunction and liver fibrogenesis/matrix remodelling in the biomarker cohort. CONCLUSIONS: Venous ammonia predicts hepatic decompensation, non-elective liver-related hospitalisation, acute-on-chronic liver failure, and liver-related death, independently of established prognostic indicators including C-reactive protein and hepatic venous pressure gradient. Although venous ammonia is linked with several key disease-driving mechanisms, its prognostic value is not explained by associated hepatic dysfunction, systemic inflammation, or portal hypertension severity, suggesting direct toxicity. IMPACT AND IMPLICATIONS: A recent landmark study linked ammonia levels (a simple blood test) with hospitalisation/death in individuals with clinically stable cirrhosis. Our study extends the prognostic value of venous ammonia to other important liver-related complications. Although venous ammonia is linked with several key disease-driving mechanisms, they do not fully explain its prognostic value. This supports the concept of direct ammonia toxicity and ammonia-lowering drugs as disease-modifying treatment.
format Online
Article
Text
id pubmed-9976454
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99764542023-03-02 Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease Balcar, Lorenz Krawanja, Julia Scheiner, Bernhard Paternostro, Rafael Simbrunner, Benedikt Semmler, Georg Jachs, Mathias Hartl, Lukas Stättermayer, Albert Friedrich Schwabl, Philipp Pinter, Matthias Szekeres, Thomas Trauner, Michael Reiberger, Thomas Mandorfer, Mattias JHEP Rep Research Article BACKGROUND & AIMS: Ammonia levels predicted hospitalisation in a recent landmark study not accounting for portal hypertension and systemic inflammation severity. We investigated (i) the prognostic value of venous ammonia levels (outcome cohort) for liver-related outcomes while accounting for these factors and (ii) its correlation with key disease-driving mechanisms (biomarker cohort). METHODS: (i) The outcome cohort included 549 clinically stable outpatients with evidence of advanced chronic liver disease. (ii) The partly overlapping biomarker cohort comprised 193 individuals, recruited from the prospective Vienna Cirrhosis Study (VICIS: NCT03267615). RESULTS: (i) In the outcome cohort, ammonia increased across clinical stages as well as hepatic venous pressure gradient and United Network for Organ Sharing model for end-stage liver disease (2016) strata and were independently linked with diabetes. Ammonia was associated with liver-related death, even after multivariable adjustment (adjusted hazard ratio [aHR]: 1.05 [95% CI: 1.00–1.10]; p = 0.044). The recently proposed cut-off (≥1.4 × upper limit of normal) was independently predictive of hepatic decompensation (aHR: 2.08 [95% CI: 1.35–3.22]; p <0.001), non-elective liver-related hospitalisation (aHR: 1.86 [95% CI: 1.17–2.95]; p = 0.008), and – in those with decompensated advanced chronic liver disease – acute-on-chronic liver failure (aHR: 1.71 [95% CI: 1.05–2.80]; p = 0.031). (ii) Besides hepatic venous pressure gradient, venous ammonia was correlated with markers of endothelial dysfunction and liver fibrogenesis/matrix remodelling in the biomarker cohort. CONCLUSIONS: Venous ammonia predicts hepatic decompensation, non-elective liver-related hospitalisation, acute-on-chronic liver failure, and liver-related death, independently of established prognostic indicators including C-reactive protein and hepatic venous pressure gradient. Although venous ammonia is linked with several key disease-driving mechanisms, its prognostic value is not explained by associated hepatic dysfunction, systemic inflammation, or portal hypertension severity, suggesting direct toxicity. IMPACT AND IMPLICATIONS: A recent landmark study linked ammonia levels (a simple blood test) with hospitalisation/death in individuals with clinically stable cirrhosis. Our study extends the prognostic value of venous ammonia to other important liver-related complications. Although venous ammonia is linked with several key disease-driving mechanisms, they do not fully explain its prognostic value. This supports the concept of direct ammonia toxicity and ammonia-lowering drugs as disease-modifying treatment. Elsevier 2023-01-23 /pmc/articles/PMC9976454/ /pubmed/36873421 http://dx.doi.org/10.1016/j.jhepr.2023.100682 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Balcar, Lorenz
Krawanja, Julia
Scheiner, Bernhard
Paternostro, Rafael
Simbrunner, Benedikt
Semmler, Georg
Jachs, Mathias
Hartl, Lukas
Stättermayer, Albert Friedrich
Schwabl, Philipp
Pinter, Matthias
Szekeres, Thomas
Trauner, Michael
Reiberger, Thomas
Mandorfer, Mattias
Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
title Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
title_full Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
title_fullStr Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
title_full_unstemmed Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
title_short Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
title_sort impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976454/
https://www.ncbi.nlm.nih.gov/pubmed/36873421
http://dx.doi.org/10.1016/j.jhepr.2023.100682
work_keys_str_mv AT balcarlorenz impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT krawanjajulia impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT scheinerbernhard impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT paternostrorafael impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT simbrunnerbenedikt impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT semmlergeorg impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT jachsmathias impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT hartllukas impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT stattermayeralbertfriedrich impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT schwablphilipp impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT pintermatthias impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT szekeresthomas impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT traunermichael impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT reibergerthomas impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease
AT mandorfermattias impactofammonialevelsonoutcomeinclinicallystableoutpatientswithadvancedchronicliverdisease